{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:35:24Z","timestamp":1787502924648,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Affinity chrome-mediated immunoassays (ACMIA) do not require pretreatment and have a wide calibration range and good analytical performance. To date, no studies have compared ACMIA and latex agglutination turbidimetry immunoassays (LTIA). The objective of this study was to evaluate the interchangeability of ACMIA, LTIA, and the previously developed ultra\u2013high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS\/MS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A total of 111 whole blood samples were collected from 25 patients undergoing routine everolimus therapeutic drug monitoring. The interchangeability between the 3 methods was assessed using robust Passing\u2013Bablok regression analysis and Bland\u2013Altman plots.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      All samples were quantifiable by UHPLC-MS\/MS, whereas 56 and 1 samples were below the lower limits of quantification by LTIA and ACMIA, respectively. In the robust Passing\u2013Bablok regression plots, the slopes of the regression equations between ACMIA and UHPLC-MS\/MS, LTIA and UHPLC-MS\/MS, and ACMIA and LTIA were 1.23 (95% [confidence interval] CI, 1.13\u20131.33), 0.67 (95% CI, 0.57\u20130.77), and 1.71 (95% CI, 1.43\u20132.33), respectively, with significant proportional biases indicating no interchangeability among all 3 methods. Bland\u2013Altman plots also revealed statistically significant proportional biases between ACMIA and UHPLC-MS\/MS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.012), LTIA and UHPLC-MS\/MS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and ACMIA and LTIA (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Statistically significant proportional biases were observed among the 3 methods. Blood everolimus concentration measurements should be interpreted with caution when switching the quantification methods for therapeutic drug monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001246","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T17:23:09Z","timestamp":1722446589000},"page":"717-724","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Lack of Interchangeability Between 3 Different Methods for Quantification of Everolimus in Blood: ACMIA, LTIA, and UHPLC-MS\/MS"],"prefix":"10.1097","volume":"46","author":[{"given":"Chika","family":"Miyagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-7971","authenticated-orcid":false,"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Shiraiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tatsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0000000000000260","article-title":"Therapeutic drug monitoring of everolimus: a consensus report","volume":"38","author":"Shipkova","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1046\/j.1600-6143.2004.00601.x","article-title":"Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling","volume":"4","author":"Starling","year":"2004","journal-title":"Am J Transplant"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1053-2498(02)01221-4","article-title":"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure","volume":"22","author":"Kovarik","year":"2003","journal-title":"J Heart Lung Transplant"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"121772","DOI":"10.1016\/j.jchromb.2019.121772","article-title":"A new HPLC-MS\/MS method for simultaneous determination of Cyclosporine A, Tacrolimus, Sirolimus and Everolimus for routine therapeutic drug monitoring","volume":"1128","author":"Krn\u00e1\u010d","year":"2019","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/00007691-200608000-00002","article-title":"Sensitive, high throughput HPLC-MS\/MS method with on-line sample clean-up for everolimus measurement","volume":"28","author":"Korecka","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"e5071","DOI":"10.1002\/bmc.5071","article-title":"Simultaneous quantification of cyclosporin, tacrolimus, sirolimus and everolimus in whole blood by UHPLC-MS\/MS for therapeutic drug monitoring","volume":"35","author":"Antunes","year":"2021","journal-title":"Biomed Chromatogr"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"113644","DOI":"10.1016\/j.jpba.2020.113644","article-title":"Development and validation of a simple and versatile method for the quantification of everolimus loaded in H-ferritin nanocages using UHPLC-MS\/MS","volume":"191","author":"Sottani","year":"2020","journal-title":"J Pharm Biomed Anal"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/FTD.0000000000000985","article-title":"High-sensitivity and high-throughput quantification of everolimus in human whole blood using ultrahigh-performance liquid chromatography coupled with tandem mass spectrometry","volume":"44","author":"Miyagi","year":"2022","journal-title":"Ther Drug Monit"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/FTD.0b013e3181e5c656","article-title":"Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation","volume":"32","author":"Moes","year":"2010","journal-title":"Ther Drug Monit"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clinbiochem.2010.10.005","article-title":"Comparison of blood sirolimus, tacrolimus and everolimus concentrations measured by LC-MS\/MS, HPLC-UV and immunoassay methods","volume":"44","author":"Sallustio","year":"2011","journal-title":"Clin Biochem"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/FTD.0000000000000474","article-title":"Multicenter evaluation of a new electrochemiluminescence immunoassay for everolimus concentrations in whole blood","volume":"40","author":"Verstraete","year":"2018","journal-title":"Ther Drug Monit"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/jcpt.12686","article-title":"Comparison of electrochemiluminescence immunoassay and latex agglutination turbidimetric immunoassay for evaluation of everolimus blood concentrations in renal transplant patients","volume":"43","author":"Akamine","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"e22941","DOI":"10.1002\/jcla.22941","article-title":"Accuracy evaluation of automated electrochemiluminescence immunoassay for everolimus and sirolimus compared to liquid chromatography-tandem mass spectrometry","volume":"33","author":"Lee","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/FTD.0000000000000057","article-title":"Latex-enhanced turbidimetric immunoassay for everolimus in whole blood using the Nanopia TDM everolimus assay with the JCA-BM6010 automatic analyzer","volume":"36","author":"Mori","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/FTD.0000000000001009","article-title":"Analytical performance of the new Siemens Affinity Chrome-Mediated Immunoassay everolimus assay and its interchangeability with the Thermo Quantitative Microsphere System for routine therapeutic drug monitoring of patients after solid organ transplantation","volume":"45","author":"Ialongo","year":"2023","journal-title":"Ther Drug Monit"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1515\/cclm-2022-0699","article-title":"Evaluation of the interchangeability between the new fully-automated affinity chrome-mediated immunoassay (ACMIA) and the Quantitative Microsphere System (QMS) with a CE-IVD-certified LC-MS\/MS assay for therapeutic drug monitoring of everolimus after solid organ transplantation","volume":"61","author":"Ialongo","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/FTD.0000000000000269","article-title":"Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee","volume":"38","author":"Seger","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/039463200802100311","article-title":"Quantification of sirolimus and everolimus by immunoassay techniques: test specificity and cross-reactivity evaluation","volume":"21","author":"Pieri","year":"2008","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cca.2007.01.017","article-title":"Comparison of fluorescent polarization immunoassay (FPIA) versus HPLC to measure everolimus blood concentrations in clinical transplantation","volume":"380","author":"Khoschsorur","year":"2007","journal-title":"Clin Chim Acta"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/FTD.0b013e31815b3cbf","article-title":"Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus","volume":"29","author":"Strom","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/clinchem\/46.3.365","article-title":"Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit","volume":"46","author":"Shipkova","year":"2000","journal-title":"Clin Chem"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1515\/cclm-2023-1063","article-title":"Analytical performance specifications for measurement uncertainty in therapeutic monitoring of immunosuppressive drugs","volume":"62","author":"Cattaneo","year":"2024","journal-title":"Clin Chem Lab Med"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:16:45Z","timestamp":1748956605000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001246","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"2024-04-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}